Literature DB >> 14533938

Immunophenotyping of angioimmunoblastic T-cell lymphomas by multiparameter flow cytometry.

Po-Shing Lee1, Ching-Nan Lin, Shih-Sung Chuang.   

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a distinct form of peripheral T-cell lymphoma (PTCL) frequently involving lymph nodes, spleen and bone marrow, and is associated with systemic symptoms. Its histologic features may be subtle at an early phase and difficult to diagnose. Despite the success of flow cytometry (FCM) in diagnosing B-cell neoplasm, FCM has not been widely accepted as a useful method for establishing the diagnosis of PTCL. Recently, the neoplastic T-cells in AITL have been shown to express CD10. We prospectively applied multiparameter FCM immunophenotyping to three cases of histologically confirmed AITL and identified a small (5-7%) population of CD4+/CD10+ T-cells in two cases. In one case, the CD4+/CD10+ population lacked surface signals of CD3 and CD7, but strongly expressed CD2, whereas CD45 expression was very weak; partial loss of surface CD3 was observed in the other. None of the lymph nodes with reactive hyperplasia, B-cell lymphomas, or Hodgkin's lymphoma studied during the same time period contained the CD4+/CD10+ population. These findings suggest that addition of CD4/CD10 and CD3/CD10 to FCM immunophenotyping panels is useful in the diagnosis of AITL. To the best of our knowledge, this is the first report to demonstrate CD10-expressing T-cells in AITL by FCM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14533938     DOI: 10.1078/0344-0338-00459

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  5 in total

1.  Angioimmunoblastic T-cell lymphoma mimicking Crohn's disease.

Authors:  Hae Yeon Kang; Jin-Hyeok Hwang; Young Soo Park; Soo-Mee Bang; Jong Seok Lee; Jin-Haeng Chung; Haeryoung Kim
Journal:  Dig Dis Sci       Date:  2007-03-30       Impact factor: 3.199

2.  Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology.

Authors:  Sanam Loghavi; Sa A Wang; L Jeffrey Medeiros; Jeffrey L Jorgensen; Xin Li; Zijun Y Xu-Monette; Roberto N Miranda; Ken H Young
Journal:  Leuk Lymphoma       Date:  2016-04-22

3.  CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder.

Authors:  Guillaume Lefèvre; Marie-Christine Copin; Christophe Roumier; Hélène Aubert; Martine Avenel-Audran; Nathalie Grardel; Stéphanie Poulain; Delphine Staumont-Sallé; Julien Seneschal; Gilles Salles; Kamel Ghomari; Louis Terriou; Christian Leclech; Chafika Morati-Hafsaoui; Franck Morschhauser; Olivier Lambotte; Félix Ackerman; Jacques Trauet; Sandrine Geffroy; Florent Dumezy; Monique Capron; Catherine Roche-Lestienne; Alain Taieb; Pierre-Yves Hatron; Sylvain Dubucquoi; Eric Hachulla; Lionel Prin; Myriam Labalette; David Launay; Claude Preudhomme; Jean-Emmanuel Kahn
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

4.  Critical Role of Flow Cytometric Immunophenotyping in the Diagnosis, Subtyping, and Staging of T-Cell/NK-Cell Non-Hodgkin's Lymphoma in Real-World Practice: A Study of 232 Cases From a Tertiary Cancer Center in India.

Authors:  Prashant R Tembhare; Gaurav Chatterjee; Anumeha Chaturvedi; Niharika Dasgupta; Twinkle Khanka; Shefali Verma; Sitaram G Ghogale; Nilesh Deshpande; Karishma Girase; Manju Sengar; Bhausaheb Bagal; Hasmukh Jain; Dhanalaxmi Shetty; Sweta Rajpal; Nikhil Patkar; Tushar Agrawal; Sridhar Epari; Tanuja Shet; Papagudi G Subramanian; Sumeet Gujral
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

5.  PD-1 combined with TRBC1 and pan-T cell antibodies for robustly monitoring angioimmunoblastic T-cell lymphoma.

Authors:  Chunyan Wang; Li Zhu; Songya Liu; Shujuan Yi; Min Xiao; Yicheng Zhang; Xia Mao
Journal:  Front Med (Lausanne)       Date:  2022-09-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.